May 25 Sepsis diagnosis with procalcitonin is now easier and more accessible
The use of diagnostic tests at the point of patient care known as "point-of-care" tests or POCT, consists of making determinations from clinical samples, always under the premise that the results are available within a period of time. immediate and 100% reliable.
This information allows the health professional to make quick clinical decisions, based on rigorous data, reducing empirical decision-making, which translates into an improvement in the quality of health care.
Sepsis specialists are well aware of the diagnostic value offered by the determination of procalcitonin, PCT, which until now had to be requested from the laboratory with some limitations and waiting, which can negatively affect the therapeutic approach to sepsis due to its time-dependent nature.
Thanks to the global collaboration established between Thermo Fisher Scientific and Samsung for the commercialization and co-development of innovative solutions in the POCT test market, professionals will be able to perform PCT determinations with absolute reliability and confidence in the Samsung LABGEO IB10 system, a very light, easy to transport and use.
This technology makes it possible to offer rapid PCT determination with a whole blood sample, with great ease of use in the processing of the determination and with the necessary guarantee of precision.
Undoubtedly, this instrument will improve clinical diagnosis and the decision-making capacity of medical professionals in the field of sepsis, which can translate into a reduction in clinical intervention times that are critical in sepsis situations. . We all know that reducing times in sepsis is equivalent to saving lives.
The instrument will also allow, thanks to its relocation and portability, to simplify not only the diagnosis, but also the monitoring of the results of the treatment of the patient with sepsis.
Quite an advance, without a doubt.